In vitro-derived genetically altered human neutrophil precursor cells and methods for administering the same

A method of administering a genetically altered neutrophil precursor cell population, which method comprises:

• a) the ex vivo introduction of DNA into a human neutrophil precursor cell population having an absent or aberrant gene, said population comprising at least about 16% CD15+CD11b- neutrophil precursor cells and less than about 5% CD34+colony forming units, wherein at least about 60% of said precursor cells are myeloblasts and promyelocytes, wherein said DNA encodes a functional protein corresponding to said gene to produce a genetically altered neutrophil precursor cell population, wherein said genetically altered neutrophil precursor cell population produces said functional protein at therapeutically effective levels;
• and
• b) the administration of a composition comprising said genetically altered neutrophil precursor cell population to a human patient with a neutrophil anomaly.

A method of preparing a genetically altered neutrophil precursor cell population, comprising:

• a) introducing DNA ex vivo into human neutrophil progenitor cells having an absent or aberrant gene, wherein said DNA encodes a functional protein corresponding to said gene, to produce genetically altered neutrophil progenitor cells;
• and
• b) proliferating and differentiating said genetically altered neutrophil progenitor cells in vitro into a genetically altered neutrophil precursor cell population, said population comprising at least about 16% CD15+CD11b- neutrophil precursor cells and less than about 5% CD34+ colony forming units, wherein at least about 60% of said precursor cells are myeloblasts and promyelocytes, wherein said genetically altered neutrophil precursor cell population produces said protein at therapeutically effective levels.

A method of preparing a genetically altered neutrophil precursor cell population, comprising introducing DNA ex vivo into a human neutrophil precursor cell population having an absent or aberrant gene, wherein said DNA encodes a functional protein corresponding to said gene, to produce a genetically altered neutrophil precursor cell population, said population comprising at least about 16% CD15+CD11b- neutrophil precursor cells and less than about 5% CD34+ colony forming units, wherein at least about 60% of said precursor cells are myeloblasts and promyelocytes, wherein said genetically altered neutrophil precursor cell population produces said functional protein at therapeutically effective levels.

A method of administering a genetically altered neutrophil precursor cell population, which method comprises:

• a) the ex vivo introduction of DNA into a human neutrophil precursor cell population, wherein said DNA is a gene for resistance to a chemotherapeutic drug to produce a genetically altered neutrophil precursor cell population, said population comprising at least about 16% CD15+CD11b- neutrophil precursor cells and less than about 5% CD34+ colony forming units, wherein at least about 60% of said precursor cells are myeloblasts and promyelocytes, wherein said genetically altered neutrophil precursor cell population produces a protein encoded by said gene at levels sufficient for resistance to said drug;
• and
• b) the administration of a composition comprising said genetically altered neutrophil precursor cell population to a patient.

A method of preparing a genetically altered neutrophil precursor cell population, comprising:

• a) introducing DNA ex vivo into human neutrophil progenitor cells, wherein said DNA is a gene for resistance to a chemotherapeutic drug, to produce genetically altered neutrophil progenitor cells;
• and
• b) proliferating and differentiating said genetically altered neutrophil progenitor cells in vitro into a genetically altered neutrophil precursor cell population, said population comprising at least about 16% CD15+CD11b- neutrophil precursor cells and less than about 5% CD34+colony forming units, wherein at least about 60% of said precursor cells are myeloblasts and promyelocytes, wherein said genetically altered neutrophil precursor cell population produces a protein encoded by said gene at levels sufficient for resistance to said drug.

A method of preparing a genetically altered neutrophil precursor cell population, comprising introducing DNA into a human neutrophil precursor cell population ex vivo, wherein said DNA is a gene for resistance to a chemotherapeutic drug, to produce a genetically altered neutrophil precursor cell population, said genetically altered population comprising at least about 16% CD15+CD11b- neutrophil precursor cells and less than about 5% CD34+ colony forming units, wherein at least about 60% of said precursor cells are myeloblasts and promyelocytes, wherein said genetically altered neutrophil precursor cell population produces a protein encoded by said gene at levels sufficient for resistance to said drug.

A composition, comprising a genetically altered neutrophil precursor cell population, said population comprising at least about 16% CD15+CD11b- neutrophil precursor cells and less than about 5% CD34+ colony forming units, wherein at least about 60% of said precursor cells are myeloblasts and promyelocytes, wherein said genetically altered neutrophil precursor cell population produces a functional protein encoded by DNA corresponding to a gene absent or aberrant in said cells at therapeutically effective levels.

A composition, comprising a genetically altered neutrophil precursor cell population, said population comprising at least about 16% CD15+CD11b- neutrophil precursor cells and less than about 5% CD34+ colony forming units, wherein at least about 60% of said precursor cells are myeloblasts and promyelocytes, wherein said genetically altered neutrophil precursor cell population produces a protein encoded by a gene for resistance to a chemotherapeutic drug at levels sufficient for resistance to said drug.